TScan Therapeutics
Stock Forecast, Prediction & Price Target
TScan Therapeutics Financial Estimates
TScan Therapeutics Revenue Estimates
TScan Therapeutics EBITDA Estimates
TScan Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $10.14M N/A | $13.53M 33.46% | $21.04M 55.51% | Avg: $5.60M Low: $2.23M High: $8.97M avg. -73.35% | Avg: $5.22M Low: $1.98M High: $9.08M avg. -6.86% | Avg: $27.80M Low: $10.57M High: $48.37M avg. 432.30% | Avg: $66.11M Low: $25.15M High: $115.03M avg. 137.81% |
Net Income
% change YoY
| $-48.62M N/A | $-65.80M -35.33% | $-89.21M -35.57% | Avg: $-143.57M Low: $-108.23M High: $-71.50M avg. -60.92% | Avg: $-157.94M Low: $-118.07M High: $-72.81M avg. -10.01% | Avg: $-84.75M Low: $-166.26M High: $-16.49M avg. 46.34% | Avg: $-79.37M Low: $-155.71M High: $-15.44M avg. 6.34% |
EBITDA
% change YoY
| $-45.31M N/A | $-65.04M -43.54% | $-80.09M -23.14% | Avg: $-3.36M Low: $-5.38M High: $-1.34M avg. 95.79% | Avg: $-3.13M Low: $-5.45M High: $-1.19M avg. 6.86% | Avg: $-16.68M Low: $-29.02M High: $-6.34M avg. -432.30% | Avg: $-39.67M Low: $-69.01M High: $-15.09M avg. -137.81% |
EPS
% change YoY
| -$2.03 N/A | -$2.74 -34.97% | -$1.36 50.36% | Avg: -$1.33 Low: -$1.65 High: -$1.09 avg. 2.50% | Avg: -$1.35 Low: -$1.8 High: -$1.11 avg. -1.62% | Avg: -$1.29 Low: -$2.53 High: -$0.25 avg. 4.11% | Avg: -$1.21 Low: -$2.37 High: -$0.24 avg. 6.34% |
Operating Expenses
% change YoY
| $58.78M N/A | $80.17M 36.38% | $114.50M 42.82% | Avg: $12.42M Low: $4.95M High: $19.87M avg. -89.14% | Avg: $11.57M Low: $4.40M High: $20.13M avg. -6.86% | Avg: $61.59M Low: $23.43M High: $107.16M avg. 432.30% | Avg: $146.48M Low: $55.73M High: $254.85M avg. 137.81% |
FAQ
What is TScan Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -4.56% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -108.23M, average is -143.57M and high is -71.50M.
What is TScan Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 122.47% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $2.23M, average is $5.60M and high is $8.97M.
What is TScan Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 2.83% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.65, average is -$1.33 and high is $-1.09.
What is the best performing analyst?
In the last twelve months analysts have been covering TScan Therapeutics stock. The most successful analyst is Justin Zelin.